Exhibitors & sponsors
Choose from a variety of sponsorship and commercial options to raise your profile and position your company as a thought leader in the community.
Reasons why being a sponsor is a brilliant marketing strategy
- Highly targeted marketing – reach your community
- Brand awareness & recognition – logo and advertisement placement
- Access to knowledge – find out about new research being undertaken
- Engage with your audience – at the event and online
- Media exposure - benefit from being promoted throughout Elsevier’s marketing process
- Enhance credibility – highlight your company’s expertise to a captive audience
- Generate new sales & form new partnerships – with registrants, vendors and speakers
- Leveraged lead generation - the chance to be recommended to attendees’ connections
To discuss your requirements or to book sponsorship or exhibit space please contact:
Gene Tools, LLC
Gene Tools, LLC produces and markets Morpholino oligos for antisense applications and ancillary products for basic research. We are also engaged in research relating to delivery of Morpholino oligos into cells and use of Morpholino oligos as probes and in diagnostic systems.
National ALS Biorepository
The National ALS Biorepository is a component of the National ALS Registry that collects, processes, and stores a variety of biological samples from a geographically representative sample of persons with ALS. Blood, serum, plasma, DNA, RNA, urine, hair and nails were collected from living participants. In addition, brain, spinal cord, CSF, bone, muscle, and human primary cells derived from skin are available from a subset of post-mortem participants. For information and to obtain samples, visit the National ALS Biorepository website,
https://wwwn.cdc.gov/als/ALSNationalBiorepository.aspx, or call toll free at (855) 874-6912.
The Association for Frontotemporal Degeneration (AFTD)
The Association for Frontotemporal Degeneration (AFTD) is a non-profit organization working toward a world where frontotemporal degeneration (FTD) is understood, effectively diagnosed, treated, cured and ultimately prevented. Our mission spans research, support, education, advocacy and awareness. AFTD-funded research programs include a $5 million FTD Biomarkers Initiative, postdoctoral fellowships, pilot grants and an FTD Therapeutic Initiative (in partnership with the Alzheimer’s Drug Discovery Foundation). AFTD also co-founded the FTD Treatment Study Group (FTSG), a collaboration between experts from industry, academia and nonprofit agencies working together to accelerate the pace of drug development by promoting scientific interactions and partnerships between academic and industry.